PCSK9 and familial hypercholesterolemia: Therapeutic PCSK9 inhibition may therefore not only represent a treatment of hypercholesterolemia and reduce major atherosclerotic events but also provide additional benefits beyond cholesterol metabolism through stimulation of glucose uptake and mitochondrial biogenesis thereby influencing cardiac function.